Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

NZ sharemarket starts new week up 0.2%
Markets Market Close

NZ sharemarket starts new week up 0.2%

The S&P/NZX 50 Index closed at 13,499.04, up 34.58 points or 0.26%.

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure
Retail

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure

Continued margin pressure and an unsustainable cost base have led The Warehouse Group to implement a comprehensive cost reset programme, something which could see head office roles slashed to save costs.Chief executive Mark Stirton said the group’s shareholders expect decisive ac...

Banks accelerate crackdown on ‘mule’ scammers
Finance

Banks accelerate crackdown on ‘mule’ scammers

New technology picks up crooked “muleteers” more quickly.